CRI programs have been instrumental in pioneering the field and funding discoveries, offering hope for the ultimate prevention and treatment of cancer using our immune system.
Watch interviews with our scientists to learn more about their groundbreaking research and its impact on patients, roundtable discussions from experts at CRI conferences and meetings, as well as public service announcements highlighting CRI's role in the field of cancer immunotherapy.
When Sharon Belvin learned that she had advanced melanoma at 22 years old, she enrolled in a CRI-funded clinical trial for a new antibody therapy called anti-CTLA-4. Today, the mother of two is still cancer free. Read more about her story and other cancer survivors who used these powerful new treatments called immunotherapies.
Stay up-to-date with the latest cancer immunotherapy news from CRI by signing up for our e-newsletter or alerts.